Viatris在日本获批Effexor®用于成人广泛性焦虑症治疗 创新产品组合再获突破

美股速递
Yesterday

Viatris Inc.宣布其抗焦虑药物Effexor®正式获得日本监管机构批准,适用于成人广泛性焦虑症(GAD)的治疗。此次获批标志着该公司创新产品组合的战略推进取得重要进展。

该药物在日本市场的准入将为企业拓展神经精神疾病治疗领域提供新的增长动能,同时强化Viatris在亚太地区专科药物市场的布局。此次获批也体现了公司持续通过引入差异化治疗方案来满足临床未竟需求的承诺。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10